Table 1.
Patients’ characteristics
| Patient | Age/ gender |
Disease | HLA-A | HLA-B | HLA-C | Sample | Total no of identified peptides* | No of putative HLA ligands† | % of HLA ligands |
| P1 | 68 /M | Heart failure | 26:01/68:01 | 38:01/50:01 | 06:02/12:03 | Pleural fluids | 1718 | 1385 | 81 |
| Bulk cells | 893 | 315 | 35 | ||||||
| P2 | 82 /M | Lung adenocarcinoma | 01:01/26:01 | 41:01/38:01 | 12:03/17:01 | Pleural fluids | 3001 | 2704 | 90 |
| Bulk cells | 3183 | 2690 | 85 | ||||||
| P3 | 42 /F | Lung adenocarcinoma | 03:01/33:01 | 18:01/53:01 | 04:01/05:01 | Pleural fluids | 4358 | 3800 | 87 |
| Bulk cells | 4947 | 4054 | 82 | ||||||
| Cultured cells | 3968 | 3606 | 91 | ||||||
| P4 | 75 /F | Endometrioid carcinoma | 02:01/11:01 | 40:01/44:02 | 03:04/05:01 | Pleural fluids | 1350 | 1118 | 83 |
| Bulk cells | 3886 | 3440 | 89 | ||||||
| P5 | 92 /M | Heart and kidney failure | 02:01/02:01 | 08:01/39:01 | 07:02/07:02 | Pleural fluids | 672 | 458 | 68 |
| Bulk cells | 1647 | 990 | 60 | ||||||
| P6 | 79 /M | Squamous cell carcinoma | 02:05/33:01 | 18:01/50:01 | 06:02/12:03 | Pleural fluids | 776 | 604 | 78 |
| Bulk cells | 540 | 122 | 23 | ||||||
| P7 | 61 /M | Heart and kidney failure | 02:01/03:02 | 08:01/51:01 | 07:02/07:02 | Pleural fluids | 1187 | 514 | 43 |
| P8 | 64 /M | Heart failure | 01:01/01:01 | 58:01/58:01 | 07:01/07:01 | Pleural fluids | 1613 | 1059 | 66 |
| Bulk cells | 2018 | 1552 | 77 | ||||||
| P9 | 73 /M | Kidney failure | 23:01/31:01 | 35:02/49:01 | 04:01/07:01 | Pleural fluids | 1590 | 1199 | 75 |
| Bulk cells | 3641 | 3012 | 83 | ||||||
| P10 | 92 /M | Lung adenocarcinoma | 25:01/32:01 | 18:01/43:01 | 04:01/12:03 | Pleural fluids | 2188 | 1407 | 64 |
| Bulk cells | 1354 | 779 | 58 | ||||||
| P11 | 60 /F | Lung adenocarcinoma | 23:01/26:01 | 38:01/49:01 | 07:01/12:03 | Pleural fluids | 6095 | 4965 | 81 |
| Bulk cells | 7886 | 6740 | 85 | ||||||
| Cultured cells | 4696 | 3670 | 78 | ||||||
| P12 | 64 /F | Lung adenocarcinoma | 01:01/32:01 | 15:17/49:01 | 07:01/07:01 | Pleural fluids | 1981 | 1409 | 71 |
| Bulk cells | 1218 | 1105 | 91 | ||||||
| P13 | 48 /F | Lung adenocarcinoma | 01:01/24:02 | 35:02/57:01 | 04:01/06:02 | Pleural fluids | 5418 | 4492 | 83 |
| Bulk cells | 5945 | 5146 | 87 | ||||||
| Medium | 1066 | 719 | 67 | ||||||
| Cultured cells | 5133 | 4598 | 90 | ||||||
| Plasma | 4004 | 2955 | 74 | ||||||
| P14 | 72 /F | Lung adenocarcinoma | 03:01/11:01 | 14:02/35:01 | 04:01/08:02 | Pleural fluids | 5605 | 4600 | 82 |
| Bulk cells | 5477 | 3726 | 68 | ||||||
| Total no of identified unique peptides | 39 669 | 32 970 | 83 | ||||||
*The number of peptides identified from the purification of 400 mL pleural effusions.
†Putative ligands are peptides that fit the sequence consensus motifs of the patients’ HLA allotypes.
F, female; HLA, human leucocyte antigen; M, male.